Vectura Group Plc (VEGPF) 2.2732 $VEGPF
Lung Transplantation - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhlntx/lung) has announced the addition of the "Lung Transplantation - Pipeline Review, H1 2014" report to their offering. 'Lung Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. Scope - A snapshot of the global therapeutic scenario for Lung Transplantation. - A review of the Lung Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lung Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Lung Transplantation Overview Therapeutics Development Pipeline Products for Lung Transplantation - Overview Pipeline Products for Lung Transplantation - Comparative Analysis Lung Transplantation - Therapeutics under Development by Companies Lung Transplantation - Pipeline Products Glance Late Stage Products Early Stage Products Lung Transplantation - Companies Involved in Therapeutics Development Lung Transplantation - Therapeutics Assessment Drug Profiles cyclosporine - Drug Profile EZ-2053 - Drug Profile Elafin - Drug Profile Respiratory and Inflammatory Diseases Program - Drug Profile VR-909 - Drug Profile Lung Transplantation - Recent Pipeline Updates Lung Transplantation - Product Development Milestones Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Quark Pharmaceuticals, Inc. Vectura Group plc Proteo, Inc. APT Pharmaceuticals, Inc. (Inactive) Neopharm Ltd. For more information visit http://www.researchandmarkets.com/research/lhlntx/lung About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Erectile Dysfunction Clinical Trials Review Report, H2 2013
M2 - Thu Jan 09, 10:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/mpz4sf/erectile) has announced the addition of the "Erectile Dysfunction Global Clinical Trials Review, H2, 2013" report to their offering. This report provides elemental information and data relating to the clinical trials on Erectile Dysfunction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Erectile Dysfunction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Bayer AG - Pfizer Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Vivus, Inc. - Johnson & Johnson - SK Chemicals Co., Ltd. - Dong-A Socio Holdings Co Ltd - Warner Chilcott Plc - Vectura Group plc For more information visit http://www.researchandmarkets.com/research/mpz4sf/erectile
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w94m9s/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2013" report to their offering. 'Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD). Scope - A snapshot of the global therapeutic scenario for Chronic Obstructive Pulmonary Disease (COPD). - A review of the Chronic Obstructive Pulmonary Disease (COPD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Chronic Obstructive Pulmonary Disease (COPD) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Boehringer Ingelheim GmbH Kyowa Hakko Kirin Co., Ltd. Osiris Therapeutics, Inc. EpiGenesis Pharmaceuticals, Inc. Amgen Inc. AstraZeneca PLC GlaxoSmithKline plc MedImmune LLC Merck & Co., Inc. Dainippon Sumitomo Pharma Co., Ltd. Bioneer Corporation Vectura Group plc Pearl Therapeutics, Inc. Nycomed International Management GmbH Novartis AG ASKA Pharmaceutical Co., Ltd Chiesi Farmaceutici SpA Dong-A Pharmaceutical Co., Ltd. Glenmark Pharmaceuticals Ltd. Kissei Pharmaceutical Co., Ltd. Laboratoires Pierre Fabre SA Meda AB Orion Corporation and many more... For more information visit http://www.researchandmarkets.com/research/w94m9s/chronic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Transplantation - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2563g/transplantation) has announced the addition of the "Transplantation - Pipeline Review, H2 2013" report to their offering. 'Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transplantation. Scope - A snapshot of the global therapeutic scenario for Transplantation. - A review of the Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Hospira, Inc. F. Hoffmann-La Roche Ltd. Kyowa Hakko Kirin Co., Ltd. Osiris Therapeutics, Inc. Athersys, Inc. GlaxoSmithKline plc Quark Pharmaceuticals, Inc. Merck & Co., Inc. AbGenomics International, Inc. Emergent BioSolutions Inc. Oxford BioMedica plc Pharming Group N.V. Vectura Group plc BioLineRx, Ltd. Novartis AG Isotechnika Pharma Inc. Samyang Corporation Astellas Pharma Inc. ViroPharma Incorporated Cell Therapeutics, Inc. Genmab A/S Exelixis, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/s2...plantation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Pulmonary Drug Delivery Systems Market 2012-2016: Intense Competition a Major Challenge Faced By the Market
M2 - Tue Jul 30, 6:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mf9vgx/global_pulmonary) has announced the addition of the "Global Pulmonary Drug Delivery Systems Market 2012-2016" report to their offering. The analysts forecast the Global Pulmonary Drug Delivery Systems market to grow at a CAGR of 14.47 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing incidence of lung-related or respiratory diseases. The Global Pulmonary Drug Delivery Systems market has also been witnessing an increasing adoption of online marketing strategy. However, intense competition among vendors could pose a challenge to the growth of this market. Commenting on the report, an analyst from the team said: The Global Pulmonary Drug Delivery Systems market is highly fragmented with a large number of vendors having significant market shares. These vendors range from large corporations producing a broad range of advanced and premium pulmonary drug delivery systems on a worldwide scale to small and medium-sized companies that concentrate on a single product line in a specific geographic region. Further, there is strong competition from cheaper private label products also. The leading vendors are presently working on low profit because of strong competition. Moreover, there is severe pricing pressure, which leads to a reduction in vendors' profit margins. Thus, intense competition is a major challenge faced by the market, and it is expected to pose a strong challenge to the market growth during the forecast period. According to the report, one of the major drivers is the increasing prevalence of lung-related or respiratory diseases such as asthma and COPD across the globe. It is estimated that around 300 million people are suffering from asthma. This influences the market for pulmonary drug delivery inhalation devices. Companies Mentioned - 3M Healthcare Ltd. - Akela Pharma Inc. - Alkermes Inc. - Allied Healthcare Products Inc. - AstraZeneca plc - Boehringer Ingelheim GmbH - CareFusion Corp. - Chiesi Farmaceutici S.p.A. - Dainippon Sumitomo Pharma Co. Ltd. - GF Health Products Inc. - GlaxoSmithKline plc - Novartis AG - Omron Healthcare Co. Ltd. - PARI Respiratory Equipment Inc. - Philips Respironics Inc. - SkyePharma plc - Sunovion Pharmaceuticals Inc. - Vectura Group plc. For more information visit http://www.researchandmarkets.com/research/mf..._pulmonary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Lung Transplantation - Pipeline Review, H1 2013
M2 - Fri Apr 12, 5:28AM CDT
Research and Markets has announced the addition of the "Lung Transplantation - Pipeline Review, H1 2013" report to their offering. 'Lung Transplantation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. Scope - A snapshot of the global therapeutic scenario for Lung Transplantation. - A review of the Lung Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lung Transpl
Erectile Dysfunction - Pipeline Review, H1 2013
M2 - Mon Mar 25, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hp2gn2/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Erectile Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Erectile Dysfunction. Scope - A snapshot of the global therapeutic scenario for Erectile Dysfunction. - A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline proje
Premature Ejaculation - Pipeline Review, H1 2013
M2 - Thu Mar 21, 3:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpptkh/premature) has announced the addition of the "Premature Ejaculation - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Premature Ejaculation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Premature Ejaculation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Premature Ejaculation. Scope - A snapshot of the global therapeutic scenario for Premature Ejaculation. - A review of the Premature Ejaculation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipelin
Migraine - Pipeline Review, H1 2013
M2 - Tue Mar 12, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wqgjw4/migraine) has announced the addition of Global Markets Direct's new report "Migraine - Pipeline Review, H1 2013" to their offering. Global Markets Direct's, 'Migraine - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. Migraine - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Migraine. - A review of the Mi
Cystic Fibrosis - Pipeline Review, H2 2012
M2 - Tue Jan 08, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/p9x3z6/cystic_fibrosis) has announced the addition of Global Markets Direct's new report "Cystic Fibrosis - Pipeline Review, H2 2012" to their offering. 'Cystic Fibrosis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cystic Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. Scope - A snapshot of the global therapeutic scenario for Cystic Fibrosis. - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monothe
Lung Transplantation - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhlntx/lung) has announced the addition of the "Lung Transplantation - Pipeline Review, H1 2014" report to their offering. 'Lung Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. Scope - A snapshot of the global therapeutic scenario for Lung Transplantation. - A review of the Lung Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lung Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Lung Transplantation Overview Therapeutics Development Pipeline Products for Lung Transplantation - Overview Pipeline Products for Lung Transplantation - Comparative Analysis Lung Transplantation - Therapeutics under Development by Companies Lung Transplantation - Pipeline Products Glance Late Stage Products Early Stage Products Lung Transplantation - Companies Involved in Therapeutics Development Lung Transplantation - Therapeutics Assessment Drug Profiles cyclosporine - Drug Profile EZ-2053 - Drug Profile Elafin - Drug Profile Respiratory and Inflammatory Diseases Program - Drug Profile VR-909 - Drug Profile Lung Transplantation - Recent Pipeline Updates Lung Transplantation - Product Development Milestones Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Quark Pharmaceuticals, Inc. Vectura Group plc Proteo, Inc. APT Pharmaceuticals, Inc. (Inactive) Neopharm Ltd. For more information visit http://www.researchandmarkets.com/research/lhlntx/lung About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Erectile Dysfunction Clinical Trials Review Report, H2 2013
M2 - Thu Jan 09, 10:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/mpz4sf/erectile) has announced the addition of the "Erectile Dysfunction Global Clinical Trials Review, H2, 2013" report to their offering. This report provides elemental information and data relating to the clinical trials on Erectile Dysfunction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Erectile Dysfunction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Bayer AG - Pfizer Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Vivus, Inc. - Johnson & Johnson - SK Chemicals Co., Ltd. - Dong-A Socio Holdings Co Ltd - Warner Chilcott Plc - Vectura Group plc For more information visit http://www.researchandmarkets.com/research/mpz4sf/erectile
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w94m9s/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2013" report to their offering. 'Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD). Scope - A snapshot of the global therapeutic scenario for Chronic Obstructive Pulmonary Disease (COPD). - A review of the Chronic Obstructive Pulmonary Disease (COPD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Chronic Obstructive Pulmonary Disease (COPD) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Boehringer Ingelheim GmbH Kyowa Hakko Kirin Co., Ltd. Osiris Therapeutics, Inc. EpiGenesis Pharmaceuticals, Inc. Amgen Inc. AstraZeneca PLC GlaxoSmithKline plc MedImmune LLC Merck & Co., Inc. Dainippon Sumitomo Pharma Co., Ltd. Bioneer Corporation Vectura Group plc Pearl Therapeutics, Inc. Nycomed International Management GmbH Novartis AG ASKA Pharmaceutical Co., Ltd Chiesi Farmaceutici SpA Dong-A Pharmaceutical Co., Ltd. Glenmark Pharmaceuticals Ltd. Kissei Pharmaceutical Co., Ltd. Laboratoires Pierre Fabre SA Meda AB Orion Corporation and many more... For more information visit http://www.researchandmarkets.com/research/w94m9s/chronic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Transplantation - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2563g/transplantation) has announced the addition of the "Transplantation - Pipeline Review, H2 2013" report to their offering. 'Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transplantation. Scope - A snapshot of the global therapeutic scenario for Transplantation. - A review of the Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Hospira, Inc. F. Hoffmann-La Roche Ltd. Kyowa Hakko Kirin Co., Ltd. Osiris Therapeutics, Inc. Athersys, Inc. GlaxoSmithKline plc Quark Pharmaceuticals, Inc. Merck & Co., Inc. AbGenomics International, Inc. Emergent BioSolutions Inc. Oxford BioMedica plc Pharming Group N.V. Vectura Group plc BioLineRx, Ltd. Novartis AG Isotechnika Pharma Inc. Samyang Corporation Astellas Pharma Inc. ViroPharma Incorporated Cell Therapeutics, Inc. Genmab A/S Exelixis, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/s2...plantation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Pulmonary Drug Delivery Systems Market 2012-2016: Intense Competition a Major Challenge Faced By the Market
M2 - Tue Jul 30, 6:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mf9vgx/global_pulmonary) has announced the addition of the "Global Pulmonary Drug Delivery Systems Market 2012-2016" report to their offering. The analysts forecast the Global Pulmonary Drug Delivery Systems market to grow at a CAGR of 14.47 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing incidence of lung-related or respiratory diseases. The Global Pulmonary Drug Delivery Systems market has also been witnessing an increasing adoption of online marketing strategy. However, intense competition among vendors could pose a challenge to the growth of this market. Commenting on the report, an analyst from the team said: The Global Pulmonary Drug Delivery Systems market is highly fragmented with a large number of vendors having significant market shares. These vendors range from large corporations producing a broad range of advanced and premium pulmonary drug delivery systems on a worldwide scale to small and medium-sized companies that concentrate on a single product line in a specific geographic region. Further, there is strong competition from cheaper private label products also. The leading vendors are presently working on low profit because of strong competition. Moreover, there is severe pricing pressure, which leads to a reduction in vendors' profit margins. Thus, intense competition is a major challenge faced by the market, and it is expected to pose a strong challenge to the market growth during the forecast period. According to the report, one of the major drivers is the increasing prevalence of lung-related or respiratory diseases such as asthma and COPD across the globe. It is estimated that around 300 million people are suffering from asthma. This influences the market for pulmonary drug delivery inhalation devices. Companies Mentioned - 3M Healthcare Ltd. - Akela Pharma Inc. - Alkermes Inc. - Allied Healthcare Products Inc. - AstraZeneca plc - Boehringer Ingelheim GmbH - CareFusion Corp. - Chiesi Farmaceutici S.p.A. - Dainippon Sumitomo Pharma Co. Ltd. - GF Health Products Inc. - GlaxoSmithKline plc - Novartis AG - Omron Healthcare Co. Ltd. - PARI Respiratory Equipment Inc. - Philips Respironics Inc. - SkyePharma plc - Sunovion Pharmaceuticals Inc. - Vectura Group plc. For more information visit http://www.researchandmarkets.com/research/mf..._pulmonary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Lung Transplantation - Pipeline Review, H1 2013
M2 - Fri Apr 12, 5:28AM CDT
Research and Markets has announced the addition of the "Lung Transplantation - Pipeline Review, H1 2013" report to their offering. 'Lung Transplantation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. Scope - A snapshot of the global therapeutic scenario for Lung Transplantation. - A review of the Lung Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lung Transpl
Erectile Dysfunction - Pipeline Review, H1 2013
M2 - Mon Mar 25, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hp2gn2/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Erectile Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Erectile Dysfunction. Scope - A snapshot of the global therapeutic scenario for Erectile Dysfunction. - A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline proje
Premature Ejaculation - Pipeline Review, H1 2013
M2 - Thu Mar 21, 3:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpptkh/premature) has announced the addition of the "Premature Ejaculation - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Premature Ejaculation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Premature Ejaculation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Premature Ejaculation. Scope - A snapshot of the global therapeutic scenario for Premature Ejaculation. - A review of the Premature Ejaculation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipelin
Migraine - Pipeline Review, H1 2013
M2 - Tue Mar 12, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wqgjw4/migraine) has announced the addition of Global Markets Direct's new report "Migraine - Pipeline Review, H1 2013" to their offering. Global Markets Direct's, 'Migraine - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. Migraine - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Migraine. - A review of the Mi
Cystic Fibrosis - Pipeline Review, H2 2012
M2 - Tue Jan 08, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/p9x3z6/cystic_fibrosis) has announced the addition of Global Markets Direct's new report "Cystic Fibrosis - Pipeline Review, H2 2012" to their offering. 'Cystic Fibrosis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cystic Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. Scope - A snapshot of the global therapeutic scenario for Cystic Fibrosis. - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monothe
